专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

WO2016120219A1 CLL1-SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译： CLL1特异性多链次级抗原受体
公开(公告)号：WO2016120219A1
公开(公告)日：2016-08-04
申请号：PCT/EP2016/051470
申请日：2016-01-25
申请人： CELLECTIS , RINAT NEUROSCIENCE CORPORATION
发明人： SMITH, Julianne , VALTON, Julien , JUILLERAT, Alexandre , DUCHATEAU, Philippe , SASU, Barbra Johnson , RAJPAL, Arvind
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.
摘要翻译：本发明涉及被称为多链CAR的新一代嵌合抗原受体（CAR），其被制成对抗原CLL1特异性。这样的CAR旨在将免疫细胞特异性和反应性转向表达肿瘤抗原CLL1的恶性细胞。构成这些CAR的α，β和γ多肽被设计为在并置的位置组装，其形成更接近天然受体的柔性结构，其赋予最佳的信号转导。本发明包括多核苷酸，编码所述多链CAR的载体和在其表面表达它们的分离细胞，特别是其用于免疫治疗。本发明开辟了治疗癌症，特别是白血病的高效过继性免疫治疗策略。

3. 发明申请

WO2016120218A1 ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY 审中-公开
标题翻译：抗CLL1特异性单链抗体抗体受体（scCARS）用于癌症免疫疗法
公开(公告)号：WO2016120218A1
公开(公告)日：2016-08-04
申请号：PCT/EP2016/051469
申请日：2016-01-25
申请人： CELLECTIS , RINAT NEUROSCIENCE CORPORATION
发明人： SMITH, Julianne , VALTON, Julien , JUILLERAT, Alexandre , DUCHATEAU, Philippe , SASU, Barbra Johnson , RAJPAL, Arvind
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.
摘要翻译：本发明涉及嵌合抗原受体（CAR），其是能够将免疫细胞特异性和反应性重定向CLL1阳性细胞的重组嵌合蛋白。赋予这种CAR的工程化免疫细胞特别适用于治疗癌症，特别是白血病的免疫治疗。

4. 发明申请

WO2011104687A1 ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS 审中-公开
标题翻译：拮抗剂抗IL-7受体抗体和方法
公开(公告)号：WO2011104687A1
公开(公告)日：2011-09-01
申请号：PCT/IB2011/050792
申请日：2011-02-24
申请人： RINAT NEUROSCIENCE CORPORATION , LIN, Chia-Yang , LEE, Li-Fen , ZHAI, Wenwu
发明人： LIN, Chia-Yang , LEE, Li-Fen , ZHAI, Wenwu
IPC分类号： C07K16/28 , C12N15/13 , A61K39/395 , A61P37/00 , A61P3/10 , A61P37/06
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
摘要翻译：本发明提供了结合白细胞介素-7受体（IL-7R）的拮抗性抗体。本发明还提供了获得这样的抗体和抗体编码核酸的方法。本发明还涉及这些抗体及其抗原结合部分用于治疗和/或预防2型糖尿病和免疫学障碍（包括1型糖尿病，多发性硬化症，类风湿性关节炎，移植物抗宿主病）的治疗方法，和狼疮。

5. 发明申请

WO2008078179A1 TRKB AGONISTS FOR TREATING AUTOIMMUNE DISORDERS 审中-公开
标题翻译： TRKB用于治疗自身免疫性疾病的药物
公开(公告)号：WO2008078179A1
公开(公告)日：2008-07-03
申请号：PCT/IB2007/004145
申请日：2007-12-05
申请人： RINAT NEUROSCIENCE CORPORATION , LIN, Chia-Yang , LONG, Hua , TSAO, David
发明人： LIN, Chia-Yang , LONG, Hua , TSAO, David
IPC分类号： A61K38/18 , C07K16/18 , A61P25/28 , A61P25/16 , A61P37/00
CPC分类号： A61K38/185 , A61K2039/505 , A61K2039/54 , C07K16/2863 , C07K2317/55 , C07K2317/75 , C07K2317/92
摘要： Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies.
摘要翻译：提供酪氨酸受体激酶（TrkB）激动剂用于减少自身免疫疾病如多发性硬化中的中枢神经系统的白细胞侵袭。 TrkB激动剂包括天然存在的激动剂，例如NT4和BDNF，以及激动剂如激动剂抗体。

6. 发明申请

WO2011024110A2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS 审中-公开
标题翻译：胰高血糖素样肽-1受体（GLP-1R）激动剂治疗自身免疫性疾病
公开(公告)号：WO2011024110A2
公开(公告)日：2011-03-03
申请号：PCT/IB2010/053754
申请日：2010-08-19
申请人： RINAT NEUROSCIENCE CORPORATION , CHOU, Joyce Ching Tsu , LIN, Chia-Yang , LONG, Hua
发明人： CHOU, Joyce Ching Tsu , LIN, Chia-Yang , LONG, Hua
IPC分类号： A61K38/26 , A61K47/48 , A61P37/00
CPC分类号： A61K38/26 , A61K47/6811 , C07K14/57563 , C07K14/72
摘要： Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies.
摘要翻译：提供胰高血糖素样肽-1受体（GLP-1R）激动剂用于减少自身免疫疾病如多发性硬化症中的中枢神经系统的白细胞侵袭。 GLP-1R激动剂包括例如天然存在的激动剂，例如毒蜥外泌肽-4，以及与抗体连接的GLP-1R激动剂肽。

7. 发明申请

WO2012059882A2 ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE 审中-公开
标题翻译：工程聚氨酯共聚物及其制备方法使用转氨酶
公开(公告)号：WO2012059882A2
公开(公告)日：2012-05-10
申请号：PCT/IB2011/054899
申请日：2011-11-03
申请人： RINAT NEUROSCIENCE CORPORATION , PFIZER INC. , STROP, Pavel , DORYWALSKA, Magdalena Grazyna , RAJPAL, Arvind , SHELTON, David , LIU, Shu-Hui , PONS, Jaume , DUSHIN, Russell
发明人： STROP, Pavel , DORYWALSKA, Magdalena Grazyna , RAJPAL, Arvind , SHELTON, David , LIU, Shu-Hui , PONS, Jaume , DUSHIN, Russell
IPC分类号： A61K47/48
CPC分类号： C07K17/02 , A61K47/48369 , A61K47/48384 , A61K47/48569 , A61K47/48715 , A61K47/68 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/30 , C07K2317/31 , C07K2317/73
摘要： The present invention provides engineered polypeptide conjugates (e.g., antibody- drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
摘要翻译：本发明提供包含酰基供体谷氨酰胺标签和胺供体试剂的工程改造的多肽缀合物（例如，抗体 - 药物偶联物，毒素 - （生物相容性聚合物）缀合物，抗体 - （生物相容性聚合物）缀合物和双特异性抗体）。一方面，本发明提供了包含式（Fc-含多肽）-TA的工程改造的含Fc多肽缀合物，其中T是在特定位点工程化的含酰基供体谷氨酰胺标签，或包含由 Fc多肽工程，其中A是胺供体试剂，其中胺供体试剂与含酰基供体谷氨酰胺的标签或内源性谷氨酰胺位点特异性结合。本发明还提供了使用转谷氨酰胺酶制备工程化多肽缀合物的方法。

8. 发明申请

WO2010131185A1 BLOCKING ANTI-DKK-1 ANTIBODIES AND THEIR USES 审中-公开
标题翻译：阻断抗DKK-1抗体及其用途
公开(公告)号：WO2010131185A1
公开(公告)日：2010-11-18
申请号：PCT/IB2010/052056
申请日：2010-05-10
申请人： PFIZER INC. , RINAT NEUROSCIENCE CORPORATION , LI, Mei , PARALKAR, Vishwas Madhav , PONS, Jaume , STONE, Donna Marie
发明人： LI, Mei , PARALKAR, Vishwas Madhav , PONS, Jaume , STONE, Donna Marie
IPC分类号： C07K16/18 , A61P19/08 , A61P19/10 , A61P19/02
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N15/70 , C12N15/85
摘要： The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1 + cells. Also provided are nucleic acids encoding anti-Dkk-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-Dkk-1 antibodies and fragments thereof. Also provided are methods of preparing the antibodies and fragments thereof of the invention. Also provided are bone anabolic agents. Pharmaceutical compositions comprising the antibodies or fragments thereof of the invention are also provided. Further provided are methods of treating diseases, conditions and disorders, such as bone disorders, which result in a loss of bone. Methods of treating or preventing a loss of bone mass, methods of inducing increased bone mass, and methods of inducing Wnt activity are also provided.
摘要翻译：本发明提供了与Dkk-1结合的抗体及其片段，特别是结合Dkk-1的人源化抗体及其片段，更具体地，涉及与Dkk-1结合的完全人源化抗体和免疫功能片段。还提供了与抗小鼠Dkk-1单克隆抗体与Dkk-1 +细胞的结合竞争的抗体及其片段。还提供了编码抗-Dkk-1抗体或其片段的核酸，以及掺入这些核酸用于重组表达抗-Dkk-1抗体及其片段的表达载体和宿主细胞。还提供了制备本发明的抗体及其片段的方法。还提供骨合成代谢剂。还提供了包含本发明的抗体或其片段的药物组合物。还提供了治疗导致骨丢失的疾病，病症和障碍（例如骨骼疾病）的方法。还提供了治疗或预防骨量丧失的方法，诱导骨量增加的方法和诱导Wnt活性的方法。

9. 发明申请

WO2010029513A2 PCSK9 ANTAGONISTS 审中-公开
标题翻译： PCSK9拮抗剂
公开(公告)号：WO2010029513A2
公开(公告)日：2010-03-18
申请号：PCT/IB2009/053990
申请日：2009-09-11
申请人： RINAT NEUROSCIENCE CORPORATION , LIANG, Hong , ABDICHE, Yasmina Noubia , CHAPARRO RIGGERS, Javier Fernando , GOMES, Bruce Charles , HAWKINS, Julie Jia Li , PONS, Jaume , QIU, Xiayang , STROP, Pavel , WANG, Yuli , PFIZER INC.
发明人： LIANG, Hong , ABDICHE, Yasmina Noubia , CHAPARRO RIGGERS, Javier Fernando , GOMES, Bruce Charles , HAWKINS, Julie Jia Li , PONS, Jaume , QIU, Xiayang , STROP, Pavel , WANG, Yuli
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译：本发明提供了拮抗性抗体，其抗原结合部分以及与原蛋白转化酶枯草杆菌蛋白酶9型（PCSK9）结合的适体。还提供了针对肽的抗体，其中抗体与PCSK9结合。本发明进一步提供了获得这种抗体和编码抗体的核酸的方法。本发明进一步涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病，包括治疗高胆固醇血症的治疗方法。

10. 发明申请

WO2011143545A1 HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM 审中-公开
标题翻译：杂交蛋白质及其生产和净化方法
公开(公告)号：WO2011143545A1
公开(公告)日：2011-11-17
申请号：PCT/US2011/036419
申请日：2011-05-13
申请人： RINAT NEUROSCIENCE CORPORATION , HO, Weihsien , PONS, Jaume , RAJPAL, Arvind , STROP, Pavel
发明人： HO, Weihsien , PONS, Jaume , RAJPAL, Arvind , STROP, Pavel
IPC分类号： C07K16/46 , C07K16/28 , C07K16/30
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2887 , C07K16/30 , C07K16/46 , C07K2317/21 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglubulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.
摘要翻译：本发明涉及工程化的异源多聚体蛋白质，更具体地，涉及用于产生和纯化异二聚体蛋白质的方法，例如双特异性抗体和包含免疫球蛋白样铰链序列的其它异二聚体蛋白质。还提供了用于生产和纯化这些工程异二聚体蛋白的方法及其在诊断和治疗中的应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式